2024
Pathologic prostate cancer grade concordance among high-resolution micro-ultrasound, systematic transrectal ultrasound and MRI fusion biopsy
Lokeshwar S, Choksi A, Smani S, Kong V, Sundaresan V, Sutherland R, Brito J, Renzulli J, Sprenkle P, Leapman M. Pathologic prostate cancer grade concordance among high-resolution micro-ultrasound, systematic transrectal ultrasound and MRI fusion biopsy. Urologic Oncology Seminars And Original Investigations 2024 PMID: 39521675, DOI: 10.1016/j.urolonc.2024.10.018.Peer-Reviewed Original ResearchMRI-TRUSMRI-TRUS fusionImage-guided biopsyFusion biopsyGG upgradingTRUS biopsyBiopsy strategyBiopsy typeNo significant differencePathological concordanceBiopsy techniqueHigh-resolution micro-ultrasoundMRI-TRUS fusion biopsyMultivariate logistic-regression analysisMRI fusion biopsySystematic transrectal ultrasoundProstate cancer patientsSignificant differenceMicro-ultrasoundLogistic-regression analysisMultivariable-analysisPathological downgradingPathological upgradingRandomized controlled trialsProstate biopsyRisk Factors and Contemporary Management Options for Pain and Discomfort Experienced During a Prostate Biopsy
Diaz G, Webb L, Rabil M, Lokeshwar S, Choksi A, Leapman M, Sprenkle P. Risk Factors and Contemporary Management Options for Pain and Discomfort Experienced During a Prostate Biopsy. Current Urology Reports 2024, 25: 243-252. PMID: 38896314, DOI: 10.1007/s11934-024-01220-w.Peer-Reviewed Original ResearchProstate biopsyRisk factorsEffective pain management strategiesDiagnosed prostate cancerPain management strategiesIn-office proceduresModern management optionsNonadherence to treatmentContemporary management optionsEnhance patient comfortInnovative imaging modalitiesExperience of painFusion biopsyProstate volumePain intensityProstate cancerPain varyPatient ageIncreased painFollow-upIn-officeManagement optionsSurveillance adherenceBiopsyPharmacological analgesics
2022
Distribution of NCCN risk classifications using MRI-ultrasound fusion versus systematic 12 core biopsies.
Khajir G, Press B, Levi A, Sprenkle P, Leapman M. Distribution of NCCN risk classifications using MRI-ultrasound fusion versus systematic 12 core biopsies. Journal Of Clinical Oncology 2022, 40: 283-283. DOI: 10.1200/jco.2022.40.6_suppl.283.Peer-Reviewed Original ResearchMRI-ultrasound fusion biopsyNCCN risk classificationMRI-ultrasound fusionFusion biopsyLower riskActive surveillanceNCCN riskSystematic biopsyCore biopsyRisk classificationFirst-time biopsyInitial active surveillanceProportion of patientsMajority of patientsEra of MRIPrimary study objectiveProstate cancer risk classificationNCCN definitionsMedian PSASurveillance biopsiesBiopsy cohortRetrospective studySingle institutionProstate cancerBiopsy
2018
MP77-07 HOW MANY CORES ARE NEEDED TO DETECT CLINICALLY SIGNIFICANT PROSTATE CANCER ON TARGETED MRI-ULTRASOUND FUSION BIOPSY?
Lu A, Amirkhiz K, Nguyen K, Leapman M, Sprenkle P. MP77-07 HOW MANY CORES ARE NEEDED TO DETECT CLINICALLY SIGNIFICANT PROSTATE CANCER ON TARGETED MRI-ULTRASOUND FUSION BIOPSY? Journal Of Urology 2018, 199: e1029-e1030. DOI: 10.1016/j.juro.2018.02.2595.Peer-Reviewed Original ResearchRole of core location in targeted MRI-ultrasound fusion biopsy of prostate lesions.
Lu A, Ghabili K, Nguyen K, Sprenkle P. Role of core location in targeted MRI-ultrasound fusion biopsy of prostate lesions. Journal Of Clinical Oncology 2018, 36: 136-136. DOI: 10.1200/jco.2018.36.6_suppl.136.Peer-Reviewed Original ResearchCancer detection rateFusion biopsyProstate lesionsSignificant cancerProstate cancerSignificant cancer detection rateMRI-US fusion biopsyHigher PIRADS scoresHigh Gleason scoreSignificant prostate cancerMRI-ultrasound fusion biopsyProstate Imaging ReportingClinical suspicionGleason scorePIRADS scoreBiopsy histologyTemplate biopsyDetection rateLesion volumePathology gradeBiopsy coresMultiparametric MRILesion basisBiopsyImaging ReportingOutcomes of serial MRI/ultrasound fusion targeted biopsy in men with very low-risk and low-risk prostate cancer managed with active surveillance.
Hsiang W, Ghabili K, Syed J, Nguyen K, Suarez-Sarmiento A, Leapman M, Sprenkle P. Outcomes of serial MRI/ultrasound fusion targeted biopsy in men with very low-risk and low-risk prostate cancer managed with active surveillance. Journal Of Clinical Oncology 2018, 36: 114-114. DOI: 10.1200/jco.2018.36.6_suppl.114.Peer-Reviewed Original ResearchMRI/US fusion biopsyLow-risk prostate cancerNational Comprehensive Cancer NetworkFusion biopsyActive surveillanceSystematic biopsyProstate cancerGleason upgradeMagnetic resonance imagingPSA densitySubsequent biopsyFavorable-risk prostate cancerMRI/ultrasound fusionSerial magnetic resonance imagingProportion of patientsRisk prostate cancerComprehensive Cancer NetworkLow-risk criteriaRisk of reclassificationLogistic regression modelsBiopsy upgradeMedian PSAGleason scoreHigher PSAInstitutional databaseHow many cores are needed to detect clinically significant prostate cancer on targeted MRI-ultrasound fusion biopsy?
Lu A, Ghabili K, Nguyen K, Leapman M, Sprenkle P. How many cores are needed to detect clinically significant prostate cancer on targeted MRI-ultrasound fusion biopsy? Journal Of Clinical Oncology 2018, 36: 134-134. DOI: 10.1200/jco.2018.36.6_suppl.134.Peer-Reviewed Original ResearchCancer detection rateFusion biopsyMulti-parametric MRILesion basisMRI-US fusion biopsyHistory of PCaHigh-grade cancerSignificant prostate cancerMRI-ultrasound fusion biopsyMpMRI studiesClinical suspicionPrimary outcomeSignificant PCaLesion biopsyDetection rateProstate cancerBiopsy coresBiopsyRegion of interestLesion targetingGenitourinary radiologistsCancerLesionsPatientsOne-quarterIs PI-RADS 3/total lesion ratio associated with clinically-significant prostate cancer in patients with equivocal-risk lesions on multi-parametric MRI?
Ghabili K, Swallow M, Suarez-Sarmiento A, Syed J, Leapman M, Weinreb J, Sprenkle P. Is PI-RADS 3/total lesion ratio associated with clinically-significant prostate cancer in patients with equivocal-risk lesions on multi-parametric MRI? Journal Of Clinical Oncology 2018, 36: 149-149. DOI: 10.1200/jco.2018.36.6_suppl.149.Peer-Reviewed Original ResearchSmaller prostate volumeMulti-parametric MRISignificant prostate cancerProstate volumeProstate cancerROI ratioPSA densityGrade groupPrediction of csPCaRisk of csPCaData System (BI-RADS) category 3Prostate Imaging ReportingMpMRI findingsBiopsy databasePrior diagnosisTargeted biopsiesFusion biopsyPositive coresCsPCaUnnecessary biopsiesBiopsyMultivariate analysisPatientsImaging ReportingLesions
2017
The positive predictive value of PI-RADS 4 lesions stratified by lesion number in biopsy naïve men.
Syed J, Javier-desloges J, Nguyen K, Sheridan A, Levi A, Weinreb J, Sprenkle P. The positive predictive value of PI-RADS 4 lesions stratified by lesion number in biopsy naïve men. Journal Of Clinical Oncology 2017, 35: 29-29. DOI: 10.1200/jco.2017.35.6_suppl.29.Peer-Reviewed Original ResearchPI-RADS 4 lesionsPositive predictive valueBiopsy-naïve menNaïve menPredictive valuePI-RADS 3PI-RADS version 2PI-RADS 4Cancer detection rateChi-square testPSA densityEntire cohortMean ageFusion biopsyProstate cancerSingle lesionLesion locationGroup 2Group 1Group 3LesionsAssessment scoresLesion numberCategorical variablesFurther assessment
2016
MRI-US fusion targeted biopsy results in patients without history of prostate biopsy.
Nawaf C, Rosoff J, Weinreb J, Lu A, Levi A, Humphrey P, Schulam P, Sprenkle P. MRI-US fusion targeted biopsy results in patients without history of prostate biopsy. Journal Of Clinical Oncology 2016, 34: 150-150. DOI: 10.1200/jco.2016.34.2_suppl.150.Peer-Reviewed Original ResearchBiopsy-naive menMRI-US fusionGleason scoreProstate cancerMapping biopsyProstate biopsyCS prostate cancerPre-biopsy mpMRITemplate mapping biopsyLow-grade diseaseCancer detection rateMRI-ultrasound fusionBiopsy of lesionsMaximum Gleason scoreCS cancerPrevious biopsyPrior biopsyBiopsy resultsFusion biopsyInclusion criteriaMp-MRIPatient basisPatientsBiopsyCancerMRI-US fusion targeted biopsy results in men with a history of prior cancer.
Nawaf C, Rosoff J, Lu A, Weinreb J, Humphrey P, Levi A, Schulam P, Sprenkle P. MRI-US fusion targeted biopsy results in men with a history of prior cancer. Journal Of Clinical Oncology 2016, 34: 88-88. DOI: 10.1200/jco.2016.34.2_suppl.88.Peer-Reviewed Original ResearchMRI-US fusionGleason scoreActive surveillanceFusion biopsySignificant cancerProstate cancerGleason 6 prostate cancerPre-biopsy mpMRIPrevious prostate biopsyAppropriate risk stratificationMRI-ultrasound fusionBiopsy of lesionsMaximum Gleason scoreUpstaging rateC cancerPrior cancerPrior biopsyMapping biopsyRisk stratificationHigher PSABiopsy resultsProstate biopsyInclusion criteriaMp-MRIPatient basisMRI-US fusion targeted biopsy results in patients with a history of a prior negative biopsy.
Nawaf C, Lu A, Rosoff J, Weinreb J, Schulam P, Humphrey P, Levi A, Sprenkle P. MRI-US fusion targeted biopsy results in patients with a history of a prior negative biopsy. Journal Of Clinical Oncology 2016, 34: 90-90. DOI: 10.1200/jco.2016.34.2_suppl.90.Peer-Reviewed Original ResearchPrior negative biopsyCS cancerGleason scoreNegative MRIProstate cancerNegative biopsyCS prostate cancerMRI suspicion scoreMRI-US fusionPre-biopsy mpMRIFusion prostate biopsyMRI-ultrasound fusionSignificant prostate cancerCancer detection rateBiopsy of lesionsMaximum Gleason scoreMulti-parametric MRIElevated PSAPrevious biopsyRepeat biopsyMapping biopsyBiopsy resultsProstate biopsyFusion biopsyStandard biopsy
2015
Simplified prostate lesion grading for magnetic resonance imaging and improved cancer detection at fusion-targeted prostate biopsy.
Kardos S, Nawaf C, Fan R, Cornfeld D, Weinreb J, Schulam P, Sprenkle P. Simplified prostate lesion grading for magnetic resonance imaging and improved cancer detection at fusion-targeted prostate biopsy. Journal Of Clinical Oncology 2015, 33: 69-69. DOI: 10.1200/jco.2015.33.7_suppl.69.Peer-Reviewed Original ResearchCancer detection rateOverall cancer detection rateSignificant prostate cancerProstate cancerSystematic biopsyProstate biopsyFusion biopsyCommon solid organ malignancyEndorectal coilCores TRUS biopsyPrior negative biopsySolid organ malignanciesFusion prostate biopsyCochran-Armitage trend testCause of cancerMagnetic resonance imagingReal-time ultrasoundArmitage trend testAbnormal DRELesion stratificationElevated PSAOrgan malignanciesLesion gradingNegative biopsyTRUS biopsy